The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

BACKGROUND: Neuroblastoma is a deadly childhood cancer, and MYCN-amplified neuroblastoma (MNA-NB) patients have the worst prognoses and are therapy-resistant. While retinoic acid (RA) is beneficial for some neuroblastoma patients, the cause of RA resistance is unknown. Thus, there remains a need for...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampis, Silvia, Raieli, Salvatore, Montemurro, Luca, Bartolucci, Damiano, Amadesi, Camilla, Bortolotti, Sonia, Angelucci, Silvia, Scardovi, Anna Lisa, Nieddu, Giammario, Cerisoli, Lucia, Paganelli, Francesca, Valente, Sabrina, Fischer, Matthias, Martelli, Alberto Maria, Pasquinelli, Gianandrea, Pession, Andrea, Hrelia, Patrizia, Tonelli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055702/
https://www.ncbi.nlm.nih.gov/pubmed/35490242
http://dx.doi.org/10.1186/s13046-022-02367-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055702/
https://www.ncbi.nlm.nih.gov/pubmed/35490242
http://dx.doi.org/10.1186/s13046-022-02367-5

Ejemplares similares